Use of selected modulators of p2 purinoceptors for the prevention of damage and mortality caused by global cerebral ischemia and ischemia-reperfusion
CA 2352789 A1 · Owner: Consiglio Nazionale Delle Ricerche · Inventors: Bernardi, Giorgio; Sancesario, Giuseppe; Volonte', Cinzia
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use of compounds modulating P2 purinoceptors in particular antagonists such , as Basilen Blue E-3G (Reactive Blue 2) for the prevention of the damages due to global cerebral ischemia and ischemia-reperfusion. Said compounds reduce the mortality in case of global cerebral ischemia as well as the neuronal damage of the hippocampus.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 23, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 23, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 23, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.